Coya Therapeutics to sell 2.522M shares at $4.40 in private placement

4 days ago 7

TipRanks

Sat, January 31, 2026 astatine 7:15 AM CST 1 min read

Coya Therapeutics (COYA) announced that it has entered into a definitive securities acquisition statement for the acquisition and merchantability of an aggregate of 2.522M shares of its communal banal successful a backstage placement astatine a terms of $4.40 per share. The offering is expected to adjacent connected oregon astir January 30, taxable to the restitution of customary closing conditions. The investors successful the offering are Dr. Reddy’s (RDY), $10M, and Greenlight Capital, an existing organization stockholder of the company. The gross proceeds to the Company from the backstage placement are expected to beryllium astir $11.1M, earlier deducting offering expenses payable by the company. No broker, placement cause oregon concern banker was engaged successful the transaction. The institution intends to usage the nett proceeds to accelerate tech transportation and scale-up manufacturing activities for debased dose IL-2 to enactment the commercialized readiness of COYA 302.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See today’s best-performing stocks connected TipRanks >>

Read More connected COYA:

Disclaimer & DisclosureReport an Issue

Coya Therapeutics Reports Strong Cash Position and Runway
COYA-302: De-Risked Treg Platform With Compelling FTD Data and ALS Phase 2 Catalyst Supporting Buy Rating
Coya Therapeutics: Early COYA 302 Validation, Regulatory De-Risking, and Upcoming Catalysts Support Buy Rating
Coya Therapeutics Reports Positive Frontotemporal Dementia Study Data
Coya Therapeutics announces FDA acceptance of COYA 302 IND application

Read Entire Article